Monday, June 30, 2025 6/30/2025

New perspective on MyoD function and differentiation in rhabdomyosarcoma

Award Number: R01CA235074
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2019
PERIOD OF PERFORMANCE END DATE: 09/30/2024

Group Awards By:

View Award Description

New perspective on MyoD function and differentiation in rhabdomyosarcoma - ABSTRACT Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents in the United States. While generally very treatable, advanced RMS often proves resistant to treatment and results in poor survival. RMS is linked to a muscle lineage and is believed to result, at least in part, from a failure of the transcription factor MyoD to functionally promote terminal differentiation. Our laboratory has long studied the role of NF-κB as a regulator of skeletal muscle differentiation, and has shown that active NF-κB prevents the maturation of muscle, which is relevant in a number of diseases, including RMS. Because NF-κB is known to play an important role in the ability of a number of cancers to resist cell death, we examined whether NF-κB would have the same cell survival activity in RMS cells as a potential mechanism of chemoresistance. Interestingly, RMS cells depleted of NF-κB remained resistant to stress. This finding led us to uncover that RMS cells depend upon MyoD for cell survival. Further, we have determined that this MyoD-mediated resistance to cell death occurs through a novel transcriptional repressive function of MyoD. The goal of our project is to explore a potential new function of MyoD as a cell survival factor in the progression of RMS and unravel the manner in which MyoD is acting to repress gene transcription, potentially relevant to RMS pathogenesis. Because the current paradigm of future RMS treatments is to promote cell differentiation through stimulation of MyoD, our current findings paired with our proposed aims have the potential to alter future RMS therapies. !


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$21,077 )
2025	2023	THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	5	2/14/2025	NON-COMPETING CONTINUATION	-$21,077
														Subtotal = -$21,077

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	THE MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	5	4/30/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $346,364 )
2023	2023	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	001	5	3/15/2023	NON-COMPETING CONTINUATION	$28,275
2023	2023	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	5	11/30/2022	NON-COMPETING CONTINUATION	$318,089
														Subtotal = $346,364

Issue Date FY: 2022 ( Subtotal = $340,712 )
2022	2022	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	4	11/26/2021	NON-COMPETING CONTINUATION	$312,900
2022	2022	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	001	4	4/28/2022	NON-COMPETING CONTINUATION	$27,812
														Subtotal = $340,712

Issue Date FY: 2021 ( Subtotal = $361,369 )
2021	2021	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	001	3	1/29/2021	NON-COMPETING CONTINUATION	$18,070
2021	2021	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	3	12/15/2020	NON-COMPETING CONTINUATION	$343,299
														Subtotal = $361,369

Issue Date FY: 2020 ( Subtotal = $326,320 )
2020	2020	MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	001	2	1/17/2020	NON-COMPETING CONTINUATION	$32,632
2020	2020	MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	2	12/6/2019	NON-COMPETING CONTINUATION	$293,688
														Subtotal = $326,320

Issue Date FY: 2019 ( Subtotal = $378,491 )
2019	2019	MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Cancer Biology Research	000	1	12/27/2018	NEW	$378,491
														Subtotal = $378,491

Grand Total All Awards = $1,732,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

New perspective on MyoD function and differentiation in rhabdomyosarcoma

Award Number: R01CA235074

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2019

PERIOD OF PERFORMANCE END DATE: 09/30/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer